Hepatitis is a medical condition that mainly affects the liver, infecting the digestive system, and the brain in the long run. There are three main types of hepatitis: HAV, HBV and HCV. HCV is a major public health problem that causes inflammation to the liver. Certain medications and excessive alcohol consumption, toxins, bacterial and viral infections can cause hepatitis. Hepatitis C infection can cause acute and chronic hepatitis.
The hepatitis C virus (HCV) spreads in an infected person’s blood using standard needles or medicines used for infusion. Factors such as an increase in the number of injecting drug users, an increase in awareness, an unsatisfactory need and the planned launch of new drugs are likely to contribute to the growth of the market during the forecast period. The market is showing a trend towards pediatric combination vaccines that protect against multiple causative agents and therefore reduce the cost savings associated with packaging and administering individual vaccines.
Earlier in November, 2020, Cadila Healthcare Ltd., also known as Zydus Cadila, declared about its completion of phase two clinical trial of its Hepatitis C drug, ‘PegiHepTM’ on Covid-19 patients.
The global hepatitis C drug market is broadly diversified based on product, disease type, distribution channel, and regions. The global market hepatitis C drugs is also segmented based on product into NS5A Inhibitor, fixed-dose. On the basis of disease type, the global market is bifurcated into acute hepatitis C, and chronic hepatitis C. Further based on distribution channel, the global market is classified into hospital pharmacies, online pharmacies, and retail pharmacies, among others.
Region-wise, North America is anticipated to grow at fast-pace owing to growing patient population. Asia Pacific is foreseen to show the fastest growth amid improvement in healthcare & sanitation, rising awareness about the hepatitis vaccination, and growing access to medicines. Other regional markets such as the Middle East and Africa is on a verge to flourish in the global hepatitis C drug market.
The increase in health care costs, together with the decline in R&D activities and medical budgets, are some of the main factors that influence participants’ profitability and significantly affect market dynamics. The global hepatitis C drug market is majorly driven by leading players through their product offerings and innovation in the relative segment. This participants include Merck & Co, Bristol-Myers Squibb, Roche, AbbVie, Johnson & Johnson, Gilead Sciences, and Basel GlaxoSmith. Increased awareness of the availability of generics is also expected to increase the number of treatments and improve overall health outcomes.